Page 543 - medicina-integrativa_compress

548 PARTE II, SECCIÓN 8 TRASTORNOS AUTOINMUNITARIOS

131. Tursi A, Brandimarte G, Giorgetti GM, et al: Low-dose balsalazide 154. Ben-Ayre E, Goldin E, Wengrower E, et al: Wheat grass juice in the
plus a high-potency probiotic preparation is more effective than treatment of active distal alternative colitis. Scand J Gastroenterol
balsalazide alone or mesalazine in the treatment of acute mild-to- 37:444-449, 2002.
moderate ulcerative colitis. Med Sci Monit 10:PI126-PI131, 2004. 155. Furrie E, Macfarlane S, Kennedy A, et al: Synbiotic therapy
132. Bibiloni R, Fedorak RN, Tannock GW, et al: VSL#3 probiotic- (Bifidobacterium longum/Synergy 1) initiates resolution of
mixture induces remission in patients with active ulcerative colitis. inflammation in patients with active ulcerative colitis: A randomised
Am J Gastroenterol 100:1539-1546, 2005. controlled pilot trial. Gut 54:242-249, 2005.
133. Gionchetti P, Rizzello F, Venturi A, et al: Oral bacteriotherapy as 156. Playford RJ, Macdonald CE, Johnson WS: Colostrum and milk-
maintenance treatment in patients with chronic pouchitis: A double- derived peptide growth factors for the treatment of gastrointestinal
blind placebo controlled trial, Gastroenterology 119: 305-309, 2000. disorders. Am J Clin Nutr 72:5-14, 2000.
134. Mimura T, Rizzello F, Helwig U, et al: Once-daily high-dose 157. Khan Z, Macdonald C, Wicks AC, et al: Use of the “nutriceutical,”
probiotic therapy (VSL#3) for maintaining remission in recurrent bovine colostrum, for the treatment of distal colitis: Results from an
or refractory pouchitis. Gut 53:108-114, 2004. initial study. Aliment Pharmacol Ther 16:1917-1922, 2002.
135. Shen B, Brzezinski A, Fazio VW, et al: Maintenance therapy with a 158. Playford RJ, MacDonald CE, Calnan DP, et al: Co-administration
probiotic in antibiotic-dependent pouchitis: Experience in clinical of the health food supplement, bovine colostrum, reduces the acute
practice. Aliment Pharmacol Ther 22:721-728, 2005. non-steroidal anti-inflammatory drug-induced increase in intestinal
136. Gosselink MP, Schouten WR, van Lieshout LM, et al: Delay of permeability. Clin Sci (Lond) 100:627-633, 2001.
the first onset of pouchitis by oral intake of the probiotic strain 159. Kang OH, Kim JA, Choi YA, et al: Inhibition of interleukin-8
Lactobacillus rhamnosus GG. Dis Colon Rectum 47:876-884, 2004. production in the human colonic epithelial cell line HT-29 by 18
137. Schultz M, Timmer A, Herfarth HH, et al: Lactobacillus GG in beta-glycyrrhetinic acid. Int J Mol Med 15:981-985, 2005.
inducing and maintaining remission of Crohn’s disease. BMC 160. Langmead L, Dawson C, Hawkins C, et al: Antioxidant effects of
Gastroenterol 4:5, 2004. herbal therapies used by patients with inflammatory bowel disease:
138. Prantera C, Scribano ML, Falasco G, et al: Ineffectiveness of An in vitro study. Aliment Pharmacol Ther 16:197-205, 2002.
probiotics in preventing recurrence after curative resection for 161. Dong WG, Liu SP, Zhu HH, et al: Abnormal function of platelets
Crohn’s disease: A randomised controlled trial with Lactobacillus and role of angelica sinensis in patients with ulcerative colitis.
GG. Gut 51:405-409, 2002. World J Gastroenterol 10:606-609, 2004.
139. McFarland V, Bernasconi P: A review of a novel biotherapeutic 162. Ammon HP: Boswellic acids (components of frankincense) as the
agent: Saccharomyces boulardii. Microb Ecol Health Dis 6:157-171, active principle in treatment of chronic inflammatory diseases.
1993. Wien Med Wochenschr 152:373-378, 2002.
140. Surawicz CM, McFarland LV, Elmer G, Chinn J: Treatment of 163. Gupta I, Parihar A, Malhotra P, et al: Effects of gum resin of
recurrent Clostridium difficile colitis with vancomycin and Boswellia serrata in patients with chronic colitis. Planta Med 67:
Saccharomyces boulardii. Am J Gastroenterol 84:1285-1287, 1989. 391-395, 2001.
141. Surawicz CM, Elmer GW, Speelman P, et al: Prevention of 164. Gupta I, Parihar A, Malhotra P, et al: Effects of Boswellia serrata gum
antibiotic-associated diarrhea by Saccharomyces boulardii: A resin in patients with ulcerative colitis. Eur J Med Res 2:37-43, 1997.
prospective study. Gastroenterology 96:981-988, 1989. 165. Gerhardt H, Seifert F, Buvari P, et al: Therapy of active Crohn
142. Buts JP, Bernasconi P, Vaerman JP, Dive C: Stimulation of secretory disease with Boswellia serrata extract H 15. Z Gastroenterol 39:
IgA and secretory component of immunoglobulins in small intestine 11-17, 2001.
of rats treated with Saccharomyces boulardii. Dig Dis Sci 35:251-256, 166. Langmead L, Makins RJ, Rampton DS: Anti-inflammatory effects
1990. of aloe vera gel in human colorectal mucosa in vitro. Aliment
143. Machado-Caetano JA, Parames MT, Babo MJ, et al: Pharmacol Ther 19:521-527, 2004.
Immunopharmacological effects of Saccharomyces boulardii in 167. Langmead L, Feakins RM, Goldthorpe S, et al: Randomized, double-
healthy human volunteers. Int J Immunopharmacol 8:245-259, blind, placebo-controlled trial of oral aloe vera gel for active
1986. ulcerative colitis. Aliment Pharmacol Ther 19:739-747, 2004.
144. Guslandi M, Giollo P, Testoni PA: A pilot trial of Saccharomyces 168. Robinson M: Medical therapy of inflammatory bowel disease for the
boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15: 21st century. Eur J Surg Suppl (582):90-98, 1998.
697-698, 2003. 169. von Wietersheim J, Kohler T, Feiereis H: Relapse-precipitating life
145. Plein K, Hotz J: Therapeutic effects of Saccharomyces boulardii on events and feelings in patients with inflammatory bowel disease.
mild residual symptoms in a stable phase of Crohn’s disease with Psychother Psychosom 58:103-112, 1992.
special respect to chronic diarrhea: A pilot study. Z Gastroenterol 170. North CS, Alpers DH, Helzer JE, et al: Do life events or depression
31:129-134, 1993. exacerbate inflammatory bowel disease? A prospective study.
146. Guslandi M, Mezzi G, Sorghi M, Testoni PA: Saccharomyces Ann Intern Med 114:381-386, 1991.
boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 171. Maunder RG. Esplen MJ: Supportive-expressive group
45:1462-1464, 2000. psychotherapy for persons with inflammatory bowel disease. Can J
147. Cassone M, Serra P, Mondello F, et al: Outbreak of Saccharomyces Psychiatry 46:622-626, 2001.
boulardii subtype boulardii fungaemia in patients neighboring those 172. Jantschek G, Zeitz M, Pritsch M, et al: Effect of psychotherapy on
treated with a probiotic preparation of the organism. J Clin the course of Crohn’s disease: Results of the German prospective
Microbiol 41:5340-5343, 2003. multicenter psychotherapy treatment study on Crohn’s disease.
148. Galland L: Functional foods: Health effects and clinical applications. German Study Group on Psychosocial Intervention in Crohn’s
In Encyclopedia of Human Nutrition, 2nd ed. London, John Wiley Disease. Scand J Gastroenterol 33:1289-1296, 1998.
& Sons, 2005, pp 360-366. 173. Schwarz SP, Blanchard EB: Evaluation of a psychological treatment
149. Hallert C, Bjorck I, Nyman M, et al: Increasing fecal butyrate in for inflammatory bowel disease. Behav Res Ther 29:167-177, 1991.
ulcerative colitis patients by diet: Controlled pilot study. Inflamm 174. Robinson A, Thompson DG, Wilin W, et al: Guided self-
Bowel Dis 9:116-121, 2003. management and patient-directed follow-up of ulcerative colitis:
150. Seidner DL, Lashner BA, Brzezinski A, et al: An oral supplement A randomized trial. Lancet 358:976-981, 2001.
enriched with fish oil, soluble fiber, and antioxidants for 175. Yang C, Yan H: Observation of the efficacy of acupuncture and
corticosteroid sparing in ulcerative colitis: A randomized, controlled moxibustion in 62 cases of chronic colitis. J Tradit Chin Med
trial. Clin Gastroenterol Hepatol 3:358-369, 2005. 19:111-114, 1999.
151. Bamba T, Kanauchi O, Andoh A, Fujiyama Y: A new prebiotic from 176. Zhang X: Twenty-three cases of chronic nonspecific ulcerative colitis
germinated barley for nutraceutical treatment of ulcerative colitis. treated by acupuncture and moxibustion. J Tradit Chin Med 18:
J Gastroenterol Hepatol 17:818-824, 2002. 188-191, 1998.
152. Kanauchi O, Mitsuyama K, Homma T, et al: Treatment of ulcerative 177. Wu H, Chen H, Hua X, et al: Clinical therapeutic effect of
colitis patients by long-term administration of germinated barley drug-separated moxibustion on chronic diarrhea and its
foodstuff: multi-center open trial. Int J Mol Med 12:701-704, 2003. immunologic mechanisms. J Tradit Chin Med 17:253-258, 1997.
153. Hanai H, Kanauchi O, Mitsuyama K, et al: Germinated barley 178. Li Y, Tougas G, Chiverton SG, Hunt RH: The effect of acupuncture
foodstuff prolongs remission in patients with ulcerative colitis. on gastrointestinal function and disorders. Am J Gastroenterol
Int J Mol Med 13:643-647, 2004. 87:1372-1381, 1992.